15 results
PATH, Agence de Médecine Préventive (AMP), World Health Organization (WHO)
The MenAfriVac CTC experience in Benin: English version
Organisation Mondiale de la Santé (OMS), Agence de Médecine Préventive (AMP), PATH
Reportage sur l'utilisation du MenAfrivac en CTC
Mvundura et all
An economic evaluation of the controlled temperature chain approach for vaccine logistics: evidence from a study conducted during a meningitis A vaccine campaign in Togo
Natalya Nepomnyashch
As of May 2017, two medical laboratory scientists employed by the Sokoto State Government, jointly trained by the University of Nebraska Medical Centre and eHA are operating the lab. During the 2017...
PATH
This fact sheet describes PATH’s efforts to eliminate meningococcal meningitis epidemics from Africa, once and for all. It covers work across meningitis projects, including the development and...
Caroline L Trotter et al.
Background: In preparation for the introduction of MenAfriVac, a meningococcal group A conjugate vaccine developed for the African meningitis belt, an enhanced meningitis surveillance network was...
Simona Zipursky et al.
In October 2012, the Meningococcal A conjugate vaccine MenAfriVac was granted a label variation to allow for its use in a controlled temperature chain (CTC), at temperatures of up to 40 °C for not...
Patrick Lydon et al.
The subject of the present study was a mass campaign against meningitis A that covered three regions of Chad and resulted in the vaccination of 1 807 158 individuals in December 2011. Although 12...
Brian Greenwood
For over 100 years, large epidemics of meningococcal meningitis have occurred every few years in areas of the African Sahel and sub-Sahel known as the African meningitis belt. Until recently, the...
Damus Paquin Kouassi et al.
MenAfriVacTM is the first of the World Health Organization (WHO)’s pre-qualified vaccines to be allowed to mass vaccination campaign at a temperature below or equal to 40°C during 4 days. This new...
Ryan T Novak et al.
An affordable, highly immunogenic Neisseria meningitidis serogroup A meningococcal conjugate vaccine (PsA—TT) was licensed for use in sub-Saharan Africa in 2009. In 2010, Burkina Faso became the...
Carl E. Frasch et al.
Although many years of application of meningococcal polysaccharide vaccines have had minimal success in preventing meningococcal epidemics in the meningitis belt of Africa, collaborative efforts to...
Sandra Mounier-Jack et al.
The study seeks to evaluate the impact of the meningococcal A (MenA) vaccine introduction in Mali through mass campaigns on the routine immunization program and the wider health system.It concludes...
Estimation of vaccination coverage at the local level is essential to identify communities that may require additional support. Cluster surveys can be used in resource-poor settings, when population...
Halima Boubacar Maïnassara et al.
To inform epidemic response strategies for the African meningitis belt after a meningococcal serogroup A conjugate vaccine was introduced in 2010, the researchers compared the effectiveness and...